Optimising current therapeutic approaches to schizophrenia: The OPTiMiSE consortium

尽管现代治疗方法取得了进步(药物和心理治疗)，但精神分裂症的预后仅略有改善，而且个体差异很大。由欧洲领先的精神分裂症研究专家和澳大利亚的一个小组组成的Optimise联盟将开始一项规模和范围世界第一的为期5年的研究计划。我们将调查1000多名新近发病的精神分裂症患者的治疗反应相关生物标志物。精神分裂症是一种慢性疾病，尽管进行了现代药物和心理治疗，但结果非常不稳定，而且往往很差。墨尔本神经精神病学中心是总部设在欧洲的优化联盟的一部分，该联盟是有史以来最大的研究项目，评估精神分裂症患者对不同药物的反应不同的原因。我们将研究哪些特征可以预测哪些药物对120名首发精神分裂症患者最有帮助。

Despite modern treatments advances (medications and psychological treatments), the prognosis of schizophrenia has only improved marginally and is individually variable. The OPTiMiSE Consortium, consisting of leading experts in schizophrenia research across Europe and a group in Australia, will commence a 5-year research program world-first in scale and scope. We will investigate the biological markers related to treatment response in over 1000 individuals with recent-onset schizophrenia. Schizophrenia is a chronic disease and despite modern medication and psychological treatments the outcome is highly variable and often poor. The Melbourne Neuropsychiatry Centre is part of the European based OPTiMiSE Consortium, the largest ever research program evaluating why individuals with schizophrenia vary in response to different medications. We will examine what characteristics predict which drugs are most helpful to 120 individuals with first episode schizophrenia